Canaccord Genuity reiterated coverage of Guardant Health with a rating of Buy and set a new price target of $135.00 from $125.00 previously

Robert W. Baird initiated coverage of Guardant Health with a rating of Outperform and set a new price target of $120.00

Evercore ISI downgraded Guardant Health from Outperform to In-line and set a new price target of $105.00

Morgan Stanley resumed coverage of Guardant Health with a rating of Overweight and set a new price target of $130.00

Wolfe Research upgraded Guardant Health from Peer Perform to Outperform and set a new price target of $75.00

Wells Fargo resumed coverage of Guardant Health with a rating of Overweight and set a new price target of $72.00

Mizuho initiated coverage of Guardant Health with a rating of Outperform and set a new price target of $55.00

Barclays initiated coverage of Guardant Health with a rating of Overweight and set a new price target of $60.00

Guggenheim upgraded Guardant Health from Neutral to Buy and set a new price target of $36.00

Jefferies resumed coverage of Guardant Health with a rating of Buy and set a new price target of $32.00

S-8 - Guardant Health, Inc. (0001576280) (Filer)

10-K - Guardant Health, Inc. (0001576280) (Filer)

8-K - Guardant Health, Inc. (0001576280) (Filer)

8-K - Guardant Health, Inc. (0001576280) (Filer)

144 - Guardant Health, Inc. (0001576280) (Subject)

8-K - Guardant Health, Inc. (0001576280) (Filer)

424B5 - Guardant Health, Inc. (0001576280) (Filer)

FWP - Guardant Health, Inc. (0001576280) (Subject)

FWP - Guardant Health, Inc. (0001576280) (Subject)

424B5 - Guardant Health, Inc. (0001576280) (Filer)

4 - Guardant Health, Inc. (0001576280) (Issuer)

4 - Guardant Health, Inc. (0001576280) (Issuer)

4 - Guardant Health, Inc. (0001576280) (Issuer)

4 - Guardant Health, Inc. (0001576280) (Issuer)

4 - Guardant Health, Inc. (0001576280) (Issuer)

4 - Guardant Health, Inc. (0001576280) (Issuer)

4 - Guardant Health, Inc. (0001576280) (Issuer)

4 - Guardant Health, Inc. (0001576280) (Issuer)

4 - Guardant Health, Inc. (0001576280) (Issuer)

4 - Guardant Health, Inc. (0001576280) (Issuer)

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans' health care including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the Center for Disease Control and Prevention. "We're honored to welcome Secretary Azar to Guardant's board," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "Secretary Azar has served at the senior-most levels of government as well as th

Foundation's grant to mobile cancer screening program in Louisiana allows individuals to be screened with Guardant's Shield™ blood test in their own community Mobile screening events to be held during Colorectal Cancer Awareness Month (March) throughout northern and central Louisiana Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a collaboration with Dak Prescott's Faith Fight Finish Foundation and the mobile cancer screening program, Partners in Wellness, an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center, to increase colorectal cancer screening rates in northern and central Louisiana. This press release

Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look

Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. "Dr. Hidalgo brings a wealth of expertise and leadership in translational and clinical research, particularly in anticancer drug development," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "His extensive experience in precision oncology and his commitment to advancing oncology care make him an invaluable addition to our board." A

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the addition of Terilyn Juarez Monroe as the company's chief people officer, effective immediately. In the newly-created role, Monroe will lead the human resources function, including people operations; cultural and organizational transformation; talent acquisition; and diversity and inclusion initiatives. Amelia Merrill, who previously served as senior vice president of people, is transitioning to an advisory role with the company. "Terilyn brings deep expertise in leading, transforming, and scaling the human resources function at rapidly growing companies, and we welcome her leadership as we pursu

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced today the appointment of Musa Tariq to its board of directors, effective March 6. Currently the chief marketing officer for GoFundMe, the world's leading fundraising platform, Tariq is a distinguished marketing executive with experience leading global consumer brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230227005656/en/Musa Tariq, Chief Marketing Officer of GoFundMe, is joining the Guardant Health board of directors. (Photo: Business Wire) "We are very pleased to welcome Musa Tariq to our board of directors," said Helmy Eltoukhy, Guardan

Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib treatment Study demonstrates need to identify C797X-driven resistance and tailor therapy options appropriately for patients with EGFR-mutant NSCLC Guardant Health Inc. (NASDAQ:GH), a leading precision oncology company, and Blueprint Medicines Corporation (NASDAQ:BPMC) announced today they are presenting new data demonstrating that the EGFR C797X mutation is the most common resistance mechanism to osimertinib therapy for patients with advanced non-small cell lung cancer (NSCLC). The results ar

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Steve E. Krognes to its board of directors. Mr. Krognes is a professional independent board member in the biotech and life science sector. He currently serves as a director at Denali Therapeutics Inc., Gritstone bio, Inc. and RLS Global AB, and previously served on the board at Corvus Pharmaceuticals, Inc. "We are very pleased to welcome Steve Krognes to our board of directors," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "With over 20 years in the biotech and life science industry, Steve brings a wealth of knowledge and expertise in financial management and corporate s

Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, has appointed Myrtle Potter to serve on its Board of Directors. "We are very pleased to welcome Myrtle Potter to our Board of Directors as we continue to build and deliver on our mission of conquering cancer with data," said Helmy Eltoukhy, Guardant Health Co-CEO and Chairman of the Board. "Myrtle has extensive knowledge and experience bringing world-class therapeutics to market, and her industry expertise will be invaluable as we strive to provide patients across all stages of cancer with access to the latest advancements in precision oncology." "I am thrilled to be joining Guardant Health's Board of Directors at su

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer.

Revenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $965 to $970 million, representing year-over-year growth of 31% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights For the three-month period ended September 30, 2025, as compared to the same period of 2024: Reported total revenue of $265.2 million, an increase of 39%, driven by: Oncology revenue of $184.4 million, an increase of 31%, and approximately 74,000 oncology tests, an increase of 40% Screeni

Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test Survey findings show eligible individuals prefer a blood test for colorectal cancer and lung cancer compared with traditional screening methods Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company and its research collaborators will present data showing the critical role of blood-based testing in increasing cancer screening adherence at the American College of Gastroenterology (ACG) 2025 Annual Meeting in Phoenix, Arizona taking place Friday, October 24 – Wednesday, October 29, 2025. Building off findings from Guardant

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2025 after market close on Wednesday, October 29, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012

Revenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $915 to $925 million, representing growth of 24% to 25% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights For the three-month period ended June 30, 2025, as compared to the same period of 2024: Reported total revenue of $232.1 million, an increase of 31%, driven by: Oncology revenue of $158.7 million, an increase of 22%, and approximately 64,000 oncology tests, an increase of 30% Screening revenue of $14.8

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012,

Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights For the three-month period ended March 31, 2025, as compared to the same period of 2024: Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of $150.6 million, an increase of 20%, and approximately 59,000 oncology tests, an increase of 25% Screening revenue of $5.7 milli

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Gua

Full year 2024 total revenue growth of 31% driven by strong clinical oncology volume growth, Guardant360 ASP tailwinds, and product upgrades Expects full year 2025 total revenue to be in the range of $850 to $860 million Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights For the three-month period ended December 31, 2024, as compared to the same period of 2023: Total revenue of $201.8 million, an increase of 30% Reported approximately 57,300 oncology clinical tests (excluding Shield) and approximately 11,050 biopharma tests, an increa

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 20, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer.

SC 13G - Guardant Health, Inc. (0001576280) (Subject)

SC 13G - Guardant Health, Inc. (0001576280) (Subject)

SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)

SC 13G - Guardant Health, Inc. (0001576280) (Subject)

SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)

SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)

SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)

SC 13G - Guardant Health, Inc. (0001576280) (Subject)

SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)

SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)

Guardant Reveal demonstrates expanded utility in identifying new, primary cancers during minimal residual disease (MRD) monitoring Studies show strong performance of Guardant360 Tissue in determining tissue of origin in diagnostically challenging settings Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company and its research collaborators will present 28 abstracts, including 3 oral sessions, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California taking place April 17 - 22, 2026. Key data that will be presen

Partnership marks the first introduction of Shield™ multi-cancer detection test in the region with availability across Hong Kong, Singapore and the Philippines Eligible Manulife customers in Hong Kong, Singapore and the Philippines will gain access to the Shield MCD test beginning in April 2026 Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch of the Shield™ multi-cancer detection (MCD) laboratory developed test (LDT) in multiple markets in Asia. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, esophageal, gastric, liver, lung, ovarian and

Survey highlights barriers to colorectal cancer screening for adults 45 and over Overwhelming majority (92%) of Americans ages 45 and over believe blood-based screening should be covered with no co-pay Shield™ by Guardant is proven to increase screening rates with a 93% adherence rate by offering a quick, easy option to screen with just a blood draw Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the results of a new national survey conducted on its behalf by The Harris Poll with findings demonstrating that more than 9 out of 10 Americans ages 45 and over believe in ensuring broader coverage for blood-based colorectal cancer (CRC) screening

Strategic collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest's vast network Physicians nationwide now have the ability to order Shield Shield is proven to increase screening rates with a 93% screening adherence rate Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that the Shield™ by Guardant blood-based screening test is now widely accessible for physician order through the nationwide connectivity of Quest Diagnostics, equipping clinicians with access to blood-based screening innovation for colorectal cancer (CRC) through one of the largest diagnostic ecosystems in

Shield Across America mobile screening tour launches during Colorectal Cancer Awareness Month to address nation's dangerously low screening rates by bringing Shield blood test directly to Americans Route will focus on rural communities across the country with the lowest screening rates and highest CRC incidence and mortality Shield is proven to increase screening rates with a 93% adherence Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch of Shield Across America, a historic coast-to-coast mobile screening tour bringing Shield, the first and only FDA-approved blood test as a primary colorectal cancer (CRC) screening option and reco

1 in 3 eligible Americans avoid colorectal cancer (CRC) screenings because traditional methods are viewed as unpleasant and inconvenient Guardant's FDA-approved Shield blood test offers an easier, more convenient way to screen with a blood draw from any prescribing healthcare provider for adults 45+ at average risk for CRC Motivated by his mother's cancer fight, Dempsey is calling on Americans to prioritize getting screened this CRC Awareness Month Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its partnership with actor and cancer advocate Patrick Dempsey to increase awareness about colorectal cancer (CRC) screening and the Shield® blood

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that on February 23, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units ("RSUs") representing 41,852 shares of its common stock to 88 new non-executive employees and one non-qualified stock option award to purchase 4,965 shares of its common stock to one new non-executive employee with a grant date of February 23, 2026 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"). The RSUs and stock options were granted as inducements material to the employees entering into employment with Guardant i

Fourth quarter 2025 revenue growth of 39% broadly driven by strong performance across Oncology and Screening Expects full year 2026 total revenue to grow in the range of 27% to 30% year-over-year Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights For the three-month period ended December 31, 2025, as compared to the same period of 2024: Reported total revenue of $281.3 million, an increase of 39%, driven by: Oncology revenue of $189.9 million, an increase of 30%, and approximately 79,000 oncology tests, an increase of 38% Biop

Patient and Public Health Groups Invited to Apply for Up to 100 Shield Colorectal Cancer Blood Tests to Support Community Screening Events and Educational Outreach in March PALO ALTO, Calif., Feb. 12, 2026 /PRNewswire/ -- Ahead of Colorectal Cancer (CRC) Awareness Month in March, Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch of its Community Colorectal Cancer Screening Grant Program, designed to support community-led efforts to expand access to colorectal cancer screening throughout March. As part of the grant program, Guardant Health will provide selected patient advocacy, non-profit, public health and health-adjacent organizations with

DENVER, Feb. 10, 2026 (GLOBE NEWSWIRE) -- As artificial intelligence continues to move beyond software and automation, its impact on genomics and gene editing is becoming increasingly tangible. Recent developments among genomics and AI-enabled biotechnology companies suggest that AI-driven pattern recognition is emerging as a foundational layer for CRISPR-based innovation, with implications spanning human health and advanced biologically assembled materials. Illumina (NASDAQ:ILMN), the global leader in DNA sequencing, recently secured U.S. Medicare reimbursement for its TruSight™ Oncology Comprehensive test, expanding access to broad genomic profiling in routine cancer care. Increased rei